Company Info

Viewpoint Molecular Targeting, Inc.

Overview

Viewpoint Molecular Targeting^® is a radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents. Viewpoint’s leading lead-212-based alpha-particle radiotherapies are designed to deliver powerful alpha radiation specifically to cancer cells utilizing specialized targeting peptides. Viewpoint is also developing complementary imaging diagnostics that utilize the same targeting peptide for the purpose of personalizing treatment and optimizing patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.